Celebrating 10 years of the Antifibrotic Drug Development Summit
Year after year, attendees continue to return to our premier cross-fibrosis conference to stay ahead of the latest scientific and commercial developments in the field. This year is no exception, with significant industry news and investment flow, especially with United Therapeutics’ supplemental New Drug Application for nebulized Tyvaso® in IPF, bringing the field one step closer to the first inhaled antifibrotic treatment for the disease.
But don’t just take our word for it, see what our past attendees have to say:
On Event Content:
On Networking:
What made my experience especially enjoyable was the strong focus on practical, clinically relevant preclinical strategies for antifibrotic drug development. The summit brought together true experts in the field, and the discussions were consistently high-quality and highly applicable to real-world program planning.
This level of expertise and open discussion made the meeting not only enjoyable but also directly impactful for shaping efficient, cost-effective, and clinically relevant antifibrotic programs.
Overall, the organization, scientific depth, and quality of speakers exceeded expectations, making the event both productive and inspiring.
Manager, MatrileX laboritories, Unity Health Toronto
It was an informative conference that provided the current and future state of fibrosis drug development. What stood out for me was fibrosis scientific community and the collaborative nature of the group.
Associate Director of Bioanalysis and Biomarkers, Asahi Kasei Corporation
To me, quality of presentation/data stood out of all the other things.
Senior Scientist II, AbbVie
Great conversations with a diverse range of field members
Associate Director, Pfizer
Fantastic meeting to exchange with experts across industry and academia to understand challenges and opportunities in antifibrotic drug discovery, with the common goal to accelerate development of new treatment options for patients in need
Senior Principal Scientist, Novartis
Based on past experiences with this conference, I find it extremely valuable to connect with leaders in the fibrosis drug development community in a more intimate setting that promotes those interactions and allows me to keep up to date on the latest data and thinking in this area, while sharing our own work and receiving valuable feedback
Vice President, Research, aTyr Pharma
I attended last year's meeting, and without hesitation, it was the most valuable conference I attended. Bringing together leading scientists, clinicians, and CROs working across fibrotic diseases created an exceptional environment for sharing ideas and learning from one another. The breadth of science and the quality of the discussions made it a truly worthwhile and impactful few days
Chief Technical Officer, Animate Biosciences
Size was perfect for networking. Fabulous speaker list, relevant contents.
Scientist, Boston University
The Antifibrotic Drug Development Summit provides a unique opportunity to translate new insights from tissue homeostasis directly into the antifibrotic target engine — closing the loop between human biology and therapeutic innovation. Meetings like this are invaluable precisely because fibrosis does not respect organ boundaries: the pathogenic programs driving aberrant cellular activation and dysfunctional repair processes share common mechanistic threads, and cross-disease dialogue accelerates the pace at which we can move from biological insight to clinical proof-of-concept.
I am particularly energized by the opportunity to discuss how emerging modalities can be brought to bear on targets that conventional treatments have struggled to address.
The collaborative spirit of this forum is exactly what the field needs to translate the omics revolution into therapies that genuinely halt or reverse fibrosis, delivering truly disease-modifying outcomes to patients.
Head of Tissue Homeostasis, AbbVie
Small setting allowing to connect with other attendees. Best format for meaningful discussions.
Principal Scientist, Altos Labs
AFDD is unique among fibrosis drug development meetings because it breaks the silos of indication- and organ-specific thinking.
Principal Scientist II, Novartis
Ability to network with key leaders in the fibrosis space
Senior VP, Research Alliances, AnaBios Corporation
Fibrosis has been studied organ by organ for decades, but the closer you look at the cell biology, the more the boundaries dissolve. A pathogenic fibroblast in a scarred lung and an activated stellate cell in a cirrhotic liver are doing remarkably similar things - running the same ECM programs with the same failure to resolve. That convergence is the reason a cross-organ meeting like this is helpful - when the field gathers around shared mechanism and identifies which therapeutic approaches are moving the needle, insight from one organ can translate to others and shorten the path to medicines that work.
Chief Executive Officer, Arda Therapeutics
Excellently organized, the workshops and conference went smoothly and offered ample opportunity to get in contact with colleagues and for networking; it is not a question of one single highlight, the overall concept worked out nicely for me
Vice President, Drug Discovery & Development, Vivoryon Therapeutics
The excellent presentations and the quality of the Q&A.
Researcher, Daewoong Pharmaceutical Co., Ltd